No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina / NY / FL

SMART Medical Systems Launches its G-EYE® 760R Colonoscope in the European Endoscopy Market Through FUJIFILM Europe

Under Strategic Distribution Partnership With FUJIFILM Corporation, to Provide Synergetic Colonoscopy Solution in Fight Against Colon Cancer

Editor: What To Know

  • This effect is designed to provide enhanced visualization of the colon and was proven in numerous clinical studies to enable a substantial increase in the detection of cancerous polyps which are the precursors of colon cancer (e.
  • Withdrawal of the G-EYE® endoscope in the colon with the balloon moderately inflated centralizes the image in the colon lumen and flattens colonic folds.
  • The flagship product to be commercialized under the new partnership is the G-EYE® 760R colonoscope, integrating the G-EYE® Balloon Technology with Fujifilm’s ELUXEO system, and yielding a highly optimized colonoscopy system for screening, diagnostic and therapeutic colonoscopy.

SMART Medical Systems Ltd., a developer and manufacturer of innovative endoscopy products, announced a strategic distribution partnership empowering Fujifilm to commercialize SMART’s G-EYE® endoscope in Europe.

The G-EYE® endoscope is a conventional colonoscope onto which SMART’s G-EYE® balloon is integrated. Withdrawal of the G-EYE® endoscope in the colon with the balloon moderately inflated centralizes the image in the colon lumen and flattens colonic folds. This effect is designed to provide enhanced visualization of the colon and was proven in numerous clinical studies to enable a substantial increase in the detection of cancerous polyps which are the precursors of colon cancer (e.g., GIE Vol.89, No.3, 2019, p545-553).

The flagship product to be commercialized under the new partnership is the G-EYE® 760R colonoscope, integrating the G-EYE® Balloon Technology with Fujifilm’s ELUXEO system, and yielding a highly optimized colonoscopy system for screening, diagnostic and therapeutic colonoscopy.

“Our new partnership with Fujifilm is a solid and strategic relation substantiating our common efforts of making the G-EYE® balloon endoscope available to more hospitals and practitioners, starting in Europe,” said Gadi Terliuc, SMART’s CEO. “We are excited to make the product available by Fujifilm and gain market share with a clear focus on colonoscopy.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy